| Literature DB >> 26023344 |
Hakan Akdere1, Ilhan Oztekin2, Ersan Arda1, Tevfik Aktoz1, Fatma Nesrin Turan3, Kamil Mehmet Burgazli4.
Abstract
BACKGROUND: Chronic Nonbacterial Prostatitis (CNBP) is a condition that frequently causes long-term pain and a significant decrease in the quality of life.Entities:
Keywords: Acupuncture; Oligonol; Pain; Prostatitis; Rats; Therapy
Year: 2015 PMID: 26023344 PMCID: PMC4443389 DOI: 10.5812/ircmj.17(4)2015.26006
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Components of the Quantum Light Therapy
| Variable | Value |
|---|---|
| 860 - 960 nm | |
| 40 - 740 nm | |
| 890 - 910 nm | |
| 50 Hz | |
| 2 Hz | |
| 35 ± 10 mTl | |
| 5 min | |
| Alternating current | |
| 50/60 Hz | |
| 20 W | |
| 12 W emitter and 30 W emitter (perineum) | |
| 4 cm2 | |
| Suprapubic, urinary bladder, anterior penile, and femoral artery (bilateral) regions, mid-perineum region between testicles and anus (including prostate area) |
Figure 1.Peak Force 1 (Before Treatment) and 2 (After Treatment) Values
Data Expressed as Mean ± SD.
Peak Force, Latency Time and Total Length of Measurement Values of the Groups [a,b]
| Group | Number of Rats at the End of the Study | Peak Force 1, G Median (BCa 95 % IQR) | Peak Force 2, G Median (BCa 95 % CI) | T-1 B, S Median (BCa 95 % CI) | T-1 A, S Median (BCa 95 % CI) | T-2 B, S Median (BCa 95 % CI) | T-2 A, S Median (BCa 95 % CI) |
|---|---|---|---|---|---|---|---|
|
|
| 992.7 (113.1 - 764.1) | 456.2 (59.27 - 419.87) | 4.12 (4.27 - 6.82) | 5.23 (2.92 - 6.15) | 5.38 (5.05 - 6.88) | 6.23 (2.2 - 8.6) |
|
|
| 831.3 (82.5 - 302.5) | 519.15 (174.7 - 417.54) | 8.82 (0.70 - 7.94) | 3.1 (2.2 - 5.5) | 9.10 (0.73 - 8) | 6.5 (1.2 - 4.3) |
|
|
| 1054.7 (95.4 - 378.7) | 371.9 (80.31 - 453.05) | 8.25 (3.75 - 7.07) | 5.8 (5.8 - 8.1) | 8.78 (3.23 - 8.02) | 6.8 (3.6 - 7.6) |
|
|
| 1096.4 (45.7 - 451.7) | 381.7 (198.12 - 365.5) | 8.0 (4.80 - 7.66) | 4 (4.1 - 10.3) | 10.15 (3.58 - 6.44) | 8.3 (6.5 - 11.3) |
|
|
| 1044.6 (91.0 - 186.1) | 661.2 (312.9 - 550.6) | 8.0 (3.02 - 6.35) | 3 (3.14 - 8.94) | 8.5 (2.85 - 6.5) | 7.1 (4.9 - 8.5) |
|
|
| 911.5 (212.0 - 653.6) | 659.6 (98.5 - 360) | 11.50 (2.96 - 6.86) | 3.8 (1.7 - 8.4) | 12.54 (2.4 - 6.32) | 7.6 (4 - 7.6) |
|
|
| 1041.7 (190.4 - 823.8) | 371.4 (18.07 - 165.6) | 5.20 (1.23 - 7.19) | 5.7 (0.9 - 4.6) | 9.05 (0.75 - 7.42) | 6.05 (0.9 - 4.7) |
|
|
| 663.9 (248.3 - 536.5) | 403.4 (36.5 - 64.7) | 3.75 (0.92 - 10.51) | 8.5 (0.5 - 5.74) | 4.05 (1.45 - 10.20) | 9.2 (1.7 - 5.3) |
|
|
| 533.9 (166.0 - 310.2) | 388 (0.9 - 292.1) | 6.40 (2.23 - 7.30) | 5.42 (1.5 - 8.8) | 6.7 (1.8 - 6.01) | 6.3 (2.2 - 8.4) |
a Peak Force 1 and 2, before treatment and after treatment (G, gram); T-1 B and A, the latency time of the rat response before treatment and after treatment (S, second); T-2 B and A, the total length of the measurement before treatment and after treatment (S, second)
b Values are presented as Median (range).
Figure 2.Latency Time (A) and Total Lengths (B) of the Rat Response Through Tail Stimulation
Data expressed as mean ± SD.